Publicacións en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (80)

2024

  1. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  2. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 667-679

  3. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  4. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  5. Incidence and outcoMes of MInor stroke and high-risk traNsient ischEmic attack in NordicTus. IMMINENT study

    Neurologia

  6. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  7. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

  8. Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

    Digestive and Liver Disease

  9. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  10. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

  11. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 936-946

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness

    Journal of Parkinson's disease, Vol. 13, Núm. 2, pp. 219-231

  3. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  4. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  5. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  6. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 5, pp. 382-396

  7. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

  8. Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

    Parkinson's Disease, Vol. 2023

  9. Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin

    International Journal of COPD, Vol. 18, pp. 1691-1700